Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 5, 2014, Pages 677-687

  Petzer, Anél ^a   Grobler, Paul ^a   Bergh, Jacobus J ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

caffeine; competitive; monoamine oxidase; reversible inhibition; structure activity relationship

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CAFFEINE; MONOAMINE OXIDASE INHIBITOR;

ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; HUMAN; IC50; METABOLISM; PARKINSON DISEASE; STRUCTURE ACTIVITY RELATION;

CAFFEINE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898802448     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12193     Document Type: Article

References (31)

1. Youdim MB, Bakhle YS,. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006; 147 (Suppl. 1): S287-S296.
2. Shih JC, et al. Role of MAO A and B in neurotransmitter metabolism and behavior. Pol J Pharmacol 1999; 51: 25-29.
3. Inoue H, et al. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 1999; 291: 856-864.
4. Weyler W, Salach JI,. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 1985; 260: 13199-13207.
5. Saura J, et al. Localization of monoamine oxidases in human peripheral tissues. Life Sci 1996; 59: 1341-1349.
6. Fowler CJ, et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980; 49 (1-2): 1-20.
7. Kalaria RN, et al. Monoamine oxidases of the human brain and liver. Brain 1988; 111 (Pt 6): 1441-1451.
8. Fernandez HH, Chen JJ,. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007; 27 (12 Pt 2): 174S-185S.
9. Finberg JP, et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1- aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 1998; 52: 279-285.
10. Di Monte DA, et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res 1996; 738: 53-59.
11. Nicotra A, et al. Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology 2004; 25 (1-2): 155-165.
12. Fowler JS, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997; 18: 431-435.
13. Zesiewicz TA, Hauser RA,. Monoamine oxidase inhibitors. In:, Factor SA, Weiner WJ, eds. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos Medical Publishing, 2002: 365-378.
14. Da Prada M, et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988; 26: 31-56.
15. Prins LH, et al. Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem 2010; 45: 4458-4466.
16. Tipton KF, et al. Monoamine oxidases: certainties and uncertainties. Curr Med Chem 2004; 11: 1965-1982.
17. Fowler JS, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse 1994; 18: 86-93.
18. Vlok N, et al. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg Med Chem 2006; 14: 3512-3521.
19. Strydom B, et al. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem 2010; 18: 1018-1028.
20. Binda C, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007; 50: 5848-5852.
21. Legoabe L, et al. Monoamine oxidase inhibition by selected anilide derivatives. Eur J Med Chem 2011; 46: 5162-5174.
22. Soriato G, et al. Pharmaceutical preparations of crystalline lazabemide. Patent 2008; WO 2008010794.
23. Blicke FF, Godt HC Jr,. Reactions of 1,3-dimethyl-5,6-diaminouracil. J Am Chem Soc 1954; 76: 2798-2800.
24. Suzuki F, et al. Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl) adenosine-induced cognitive disturbance. J Med Chem 1993; 36: 2508-2518.
25. Petzer A, et al. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 2012; 258: 403-409.
26. Novaroli L, et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem 2005; 13: 6212-6217.
27. Son SY, et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008; 105: 5739-5744.
28. Binda C, et al. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002; 9: 22-26.
29. Mostert S, et al. Inhibition of monoamine oxidase by 8-[(phenylethyl) sulfanyl]caffeine analogues. Bioorg Med Chem 2012; 20: 7040-7050.
30. Pretorius J, et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 2008; 16: 8676-8684.
31. Hubálek F, et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 2005; 280: 15761-15766.